DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A better-than-expected third-quarter 2024 performance and a series of favorable coverage ...

Like Dexcom's, each system has smartphone capabilities ... Available Dexcom CGM products include: Dexcom G6 (adults and ...

Dexcom Inc是一家医疗设备公司。该公司主要专注于连续血糖监测(CGM)系统的设计、开发和商业化，供糖尿病患者和医疗保健提供者使用。其Dexcom G6是一种CGM 系统，可作为集成系统的一部分与其他兼容的医疗设备和电子接口一起使用，其中可能包括自动胰岛素剂量 ...

today announced the Dexcom G6 Continuous Glucose Monitoring (CGM) System is being worn by astronauts in space as part of the Polaris Dawn mission, which launched this morning and aims to better ...

Geneos Wealth Management Inc. lessened its position in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 2.6% in the ...

Exchange Traded Concepts LLC decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 12.4% in the ...

In June, DexCom announced the integration of its G6 CGM system with Insulet’s Omnipod 5 Automated Insulin Delivery System for Type 1 diabetes patients. The same month, the company announced the ...

Dexcom (DXCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 13. Analyst Mike Kratky from ...

Matthew Taylor, an analyst from Jefferies, reiterated the Buy rating on Dexcom (DXCM – Research Report). The associated price target remains ...

Strong Product Demand: We are upbeat about DexCom's continued strength in CGM products. DexCom demonstrated strong product demand in third-quarter 2024, highlighted by record new patient starts in ...